Last reviewed 2026-04-23 · How we verify

PRC-063 oral capsules

PRC-063 oral capsules are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain.

PRC-063 oral capsules are a serotonin-norepinephrine reuptake inhibitor (SNRI) that works by increasing the levels of serotonin and norepinephrine in the brain. Used for Chronic pain, Major depressive disorder.

At a glance

Mechanism of action

By increasing the levels of serotonin and norepinephrine, PRC-063 oral capsules help to improve mood, reduce pain, and increase energy levels. This is achieved by blocking the reuptake of these neurotransmitters, allowing them to remain in the synaptic cleft for a longer period and increasing their availability for binding to their respective receptors.

Approved indications

• Chronic pain
• Major depressive disorder

Common side effects

• Nausea
• Headache
• Dizziness
• Fatigue
• Insomnia

Key clinical trials

• PRC-063 Adult Laboratory Classroom Study in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD) (PHASE3)
• PRC-063 Classroom Study in Children (6-12 Years of Age) With ADHD (PHASE3)
• The Efficacy and Safety of PRC-063 in Adult ADHD Patients (PHASE3)
• A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD (PHASE3)
• PRC-063 in an ADULT Workplace Environment (PHASE3)
• PRC-063 in Adolescent ADHD (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• PRC-063 oral capsules CI brief — competitive landscape report
• PRC-063 oral capsules updates RSS · CI watch RSS
• Purdue Pharma, Canada portfolio CI